Search Results
Your search for AT matches 29597 pages
Showing 7301 - 7350NCCN Guidelines for Prostate Cancer: Panel Clarifies Role of Active Surveillance for Low-Risk Prostate Cancer
In October 2021, the National Comprehensive Cancer Network (NCCN) prostate caycer panel modified its guidelines (NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines®]) for low-risk prostate cancer to remove the word “preferred option” for active surveillance, giving equal weight to...
I Don’t Know Why I Got Young-Onset Colorectal Cancer
Throughout my adolescence and early adulthood, I had been plagued with digestive issues, including bouts of gastritis and constipation, which seemed normal for me and wasn’t too concerning. But by the time I turned 30, in 2015, the acid reflux I had been experiencing became so frequent and...
2021 FDA Approvals of Drugs for Cancer Treatment
Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to many novel drugs and new indications for older therapeutic agents used in oncology and hematology. NOVEMBER Pafolacianine for Ovarian Cancer Lesions: On November 29, pafolacianine (Cytalux), an imaging drug,...
Study Examines Rates of Breast and Colorectal Cancer Screening Among Rural Women
Women who live in urban areas and those residing in rural areas are screened for breast cancer at similar rates, but rural women are screened for colorectal cancer at significantly lower rates than their urban counterparts, research published by Shete et al in JAMA Network Open showed. The...
Addition of First-Line Veliparib to Chemotherapy in Advanced Squamous Cell NSCLC: No Survival Benefit in Current Smokers, but Potential Benefit Among Biomarker-Selected Patients
In a phase III trial reported in the Journal of Clinical Oncology, Suresh S. Ramalingam, MD, of Winship Cancer Institute, Emory University School of Medicine, and colleagues found that the addition of the PARP inhibitor veliparib to platinum-based chemotherapy did not improve overall survival in...
ASH Recognizes Choosing Wisely Champions at 63rd Annual Meeting
The American Society of Hematology (ASH) recognized three Choosing Wisely Champions—individuals working to tackle the overuse of hematology tests and treatments—at the 63rd ASH Annual Meeting & Exposition, held December 11–14 in Atlanta. Choosing Wisely is an initiative that seeks to advance a...
Diversity in Clinical Trials Career Development Program
The Bristol Myers Squibb Foundation, the National Medical Fellowships, and the American Association for Cancer Research (AACR) recently announced the first group of 52 physicians selected for its Diversity in Clinical Trials Career Development Program. The 52 physicians selected by an independent...
First-Line Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma: Effect on Overall Survival
As reported in The Lancet Oncology by Thomas Yau, MD, and colleagues, the phase III CheckMate 459 trial has shown no improvement in overall survival with first-line nivolumab vs sorafenib in patients with advanced hepatocellular carcinoma. Study Details In the open-label trial, 743 patients not...
Solving the Conundrum of Young-Onset Colorectal Cancer
Although research so far has failed to uncover the root causes of the development of young-onset colorectal cancer, what is certain is that although colorectal cancer rates are declining in older adults, they are on a steady rise in people younger than age 50, especially those between the ages of...
Adjuvant T-DM1/Pertuzumab vs Taxane/Trastuzumab/Pertuzumab in High-Risk HER2-Positive Breast Cancer
In the phase III KAITLIN trial reported in the Journal of Clinical Oncology, Ian E. Krop, MD, and colleagues found that adjuvant ado-trastuzumab emtansine (T-DM1) plus pertuzumab did not improve invasive disease–free survival vs a taxane plus trastuzumab/pertuzumab, both following...
Association of CD123 Expression With High-Risk Disease Characteristics and Outcomes in Pediatric AML
In an analysis from the Children’s Oncology Group AAML1031 trial reported in the Journal of Clinical Oncology, Lamble et al found that increased CD123 expression was associated with high-risk genetic alterations and poorer treatment outcomes in pediatric patients with newly diagnosed acute myeloid...
Research From the 2021 ASH Annual Meeting & Exposition
The 2021 ASH Annual Meeting & Exposition took place from December 11 to 14. This week, we’re highlighting two studies featured as late-breaking abstracts at the meeting.
Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective
The COVID-19 pandemic may have changed some aspects of health care forever. At the 2021 JADPRO Live Virtual event, a panel discussion focused on how several cancer centers faced challenges, and what changes the participants view as positive.1 JADPRO Live is an annual educational conference for...
WHO Launches a New Classification System for Pediatric Tumors, Incorporating Morphology, Immunohistochemistry Analysis, and Molecular Characteristics
A review article by Pfister et al published in Cancer Discovery summarizes the inaugural classification of pediatric tumors soon to be published by the International Agency for Research on Cancer as part of the new World Health Organization (WHO) Classification of Tumors series, including an online ...
CANDOR: Continued Progression-Free Survival Benefit With Carfilzomib, Dexamethasone, and Daratumumab vs Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
In an updated analysis of the pivotal phase III CANDOR trial reported in The Lancet Oncology, Saad Z. Usmani, MD, and colleagues found that the addition of daratumumab to carfilzomib and dexamethasone (KdD) continued to show a large progression-free survival benefit in patients with relapsed or...
Addition of Monoclonal Antibody hu14.18K322A to Chemotherapy in Pediatric Patients With Newly Diagnosed High-Risk Neuroblastoma
In a single-institution phase II trial reported in the Journal of Clinical Oncology, Furman et al found that the addition of the humanized antidisialoganglioside monoclonal antibody hu14.18K322A to chemotherapy produced high rates of early and end-of-induction response and event-free survival in...
Effect of TP53 Alterations on Outcomes of CD19-Targeted CAR T-Cell Therapy for Patients With Large B-Cell Lymphoma
In a single-center retrospective study reported in the Journal of Clinical Oncology, Shouval et al found that the presence of TP53 alterations was associated with poorer outcomes in patients treated with CD19-targeted chimeric antigen receptor (CAR) T-cell therapy (CD19–CAR-T) for relapsed or...
Impact of Small Cell Undifferentiated Histology on Outcomes in Pediatric Hepatoblastoma
In an analysis from the Children’s Oncology Group study AHEP0731 reported in the Journal of Clinical Oncology, Trobaugh-Lotrario et al found that the presence of small cell undifferentiated histology elements did not appear to adversely affect outcomes in pediatric patients with hepatoblastoma....
Colorectal Cancer Screening: Preferences of Gastroenterologists and Primary Care Clinicians
Despite the availability of several effective screening tests, colorectal cancer screening rates remain below national goals. Although colonoscopy is the most often recommended screening method, a new study has found that the preferences of primary care clinicians have shifted toward noninvasive...
Study Examines Possible Clinical Trial Bias From Undisclosed Censoring
New research published by Wilson et al in JNCCN–Journal of the National Comprehensive Cancer Network found that only 59% of oncology clinical trials studied provided adequately defined rules for censoring. The researchers examined published randomized control trials supporting U.S. Food and Drug...
ZUMA-5 Trial: Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
As reported in The Lancet Oncology by Caron A. Jacobson, MD, and colleagues, the phase II ZUMA-5 trial showed that axicabtagene ciloleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, produced high rates of durable responses in patients with relapsed or refractory...
Effect of Statin Use on Outcomes of PSA Screening for Prostate Cancer
In a Finnish study reported in JAMA Oncology, Vettenranta et al found that statin use did not appear to markedly affect the benefits of prostate-specific antigen (PSA) screening for prostate cancer. As stated by the investigators, “PSA screening for prostate cancer has resulted in a slight...
Sotorasib in Previously Treated Patients With KRAS G12C–Mutant Colorectal Cancer
In a prespecified analysis of the phase II CodeBreaK100 trial reported in The Lancet Oncology, Marwan Fakih, MD, and colleagues found that the KRAS G12C protein inhibitor sotorasib showed modest activity in patients with previously treated KRAS G12C–mutant colorectal cancer. Study Details The...
FDA Approves Abatacept-Based Combination for Prophylaxis of Acute Graft-vs-Host Disease
On December 15, the U.S. Food and Drug Administration (FDA) approved abatacept (Orencia) for the prophylaxis of acute graft-vs-host disease (GVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients aged 2 years and older undergoing hematopoietic stem...
Study Examines a Potential Approach to Mitigate CAR T-Cell Therapy Toxicity
Research demonstrating a novel approach that may reduce cytokine-release syndrome associated with chimeric antigen receptor (CAR) T-cell therapy was presented by Marcela Maus, MD, PhD, and colleagues at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 1723)...
Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab for Younger Patients With CLL
A study presented by Matthew S. Davids, MD, of Dana-Farber Cancer Institute, and colleagues at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 640) suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy may provide deep and lasting...
Neoadjuvant Chemotherapy and Mandibular Preservation in Operable Oral Cavity Cancer
In an Indian single-institution phase II study reported in the Journal of Clinical Oncology, Chaukar et al found that neoadjuvant chemotherapy was associated with mandibular preservation in approximately half of previously untreated patients undergoing surgery for squamous cell carcinoma of the...
Composite Biomarker Needed to Predict Benefit of Immunotherapy in Triple-Negative Breast Cancer
Although there is a biomarker that predicts response to the one approved immunotherapy agent for metastatic triple-negative breast cancer, “it is important to note there are no biomarkers of response to neoadjuvant immunotherapy in early-stage triple-negative breast cancer,” Elizabeth A....
Tarek H. Mouhieddine, MD, on Relapsed/Refractory Multiple Myeloma and Bispecific Antibodies
Tarek H. Mouhieddine, MD, of The Mount Sinai Hospital and The Icahn School of Medicine at Mount Sinai, discusses data that suggest patients with heavily pretreated, predominantly triple-class refractory multiple myeloma who relapse after treatment with bispecific antibodies may still have good...
American Cancer Society Releases Updated Report on Status of Cancer Disparities in the United States
The American Cancer Society recently released its report on the status of cancer disparities in the United States for 2021. Researchers analyzed comprehensive and up-to-date data on racial/ethnic and socioeconomic disparities in cancer occurrence; this includes incidence, stage at diagnosis,...
POLARIX: Pola-R-CHP vs R-CHOP for Previously Untreated Patients With DLBCL
The POLARIX study found patients with diffuse large B-cell lymphoma (DLBCL) had a significantly higher likelihood of survival without disease progression 2 years after receiving a new drug combination known as pola-R-CHP (polatuzumab vedotin-piiq with rituximab, cyclophosphamide, doxorubicin, and...
BELINDA Study: Second-Line Tisagenlecleucel Equivalent to Standard of Care for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
In an analysis of the phase III BELINDA trial presented by Bishop et al during the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract LBA-6), the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel was not found to improve event-free survival over the...
Outcomes With Adjuvant Chemoendocrine vs Endocrine Therapy in Node-Positive Breast Cancer and Association With 21-Gene Assay Recurrence Score
In an interim analysis of the phase III RxPONDER trial reported in The New England Journal of Medicine, Kevin Kalinsky, MD, and colleagues found that the addition of adjuvant chemotherapy to endocrine therapy did not improve invasive disease–free survival among women with hormone receptor–positive, ...
HHS Secretary Becerra Names Lawrence Tabak, DDS, PhD, Acting Director of NIH
Health and Human Services Secretary Xavier Becerra recently announced that Lawrence A. Tabak, DDS, PhD, Principal Deputy Director of the National Institutes of Health (NIH), will serve as Acting Director of the NIH effective December 20, 2021. Earlier this year, current NIH Director Francis S....
ZUMA-7 Primary Analysis: Second-Line Axicabtagene Ciloleucel Quadruples Event-Free Survival in Large B-Cell Lymphoma
In the primary analysis of the phase III ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel led to a fourfold increase in event-free survival over the standard of care in the second-line treatment of relapsed or refractory large B-cell lymphoma, according to...
Study Identifies Factors for Severe COVID-19 Illness Among Patients With Acute Leukemia or MDS
In separate analyses of 257 patients with acute leukemia or myelodysplastic syndrome (MDS) who developed COVID-19 and are part of the American Society of Hematology (ASH) RC COVID-19 Registry for Hematology, both neutropenia and having active MDS or leukemia (vs being in remission) were found to...
Addition of Romidepsin to CHOP in Previously Untreated Patients With Peripheral T-Cell Lymphoma
As reported in the Journal of Clinical Oncology by Bachy et al, the Lymphoma Study Association phase III Ro-CHOP trial showed no progression-free survival benefit with the addition of the histone deacetylase inhibitor romidepsin to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)...
European OnCovid Registry Analysis of Time-Dependent COVID-19 Mortality in Patients With Cancer
As reported in JAMA Oncology by researchers from the OnCovid Study Group, an updated analysis of the European OnCovid registry indicated that mortality due to COVID-19 infection has decreased over time for patients with cancer during the pandemic. Study Details The study included real-world data on ...
Immune Checkpoint Inhibitor Treatment in Patients Aged 65 and Older With Advanced Melanoma: Association Between Sex and Survival
In a study reported in JAMA Network Open, Jang et al found that women with advanced melanoma receiving combination immune checkpoint inhibitor therapy with nivolumab/ipilimumab as their most recent immune checkpoint inhibitor therapy (all with prior ipilimumab treatment) had a poorer survival...
Isatuximab/RVd Meets Primary Endpoint of MRD Negativity for Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma
For the first-line treatment of newly diagnosed, transplant-eligible patients with multiple myeloma, the achievement of measurable residual disease (MRD) negativity was significantly greater when the anti-CD38 monoclonal antibody isatuximab was added to the standard three-drug induction regimen of...
Study Reveals Gaps in Code Status Discussions Among Patients With High-Risk AML
Oncologists and health-care professionals who treat patients with high-risk acute myeloid leukemia (AML) are missing important opportunities to have end-of-life discussions at earlier stages in the disease course, when patients are best able to discuss their options and preferences. These findings...
Antibody Response to COVID-19 Vaccination in Patients With Myeloid and Lymphoid Neoplasms
According to a German study by Rotterdam et al presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 218), about 15% of people with blood cancers and other blood disorders had no vaccination-related antibodies after receiving a COVID-19 vaccine....
ASH RC COVID-19 Registry for Hematology: Risk Factors for Hospitalization and Death Among Patients With Hematologic Malignancies Infected With COVID-19
Patients with blood cancers, particularly those with more advanced disease, are at increased risk for serious COVID-19 outcomes, including an elevated chance of severe illness or death from infection, according to an analysis of more than 1,000 patients in the ASH Research Collaborative (RC)...
Ivosidenib/Azacitidine vs Azacitidine Alone in Patients With Newly Diagnosed IDH1-Mutated AML
In the phase III AGILE trial, the combination of ivosidenib and azacitidine was found to be superior in treating newly diagnosed patients with IDH1-mutated acute myeloid leukemia (AML) compared to azacitidine alone in terms of event-free survival, the study’s primary endpoint. The combination also...
Antibody Response to Second Dose of mRNA COVID-19 Vaccine in Patients With AML and MDS
In one of the largest studies to date of the antibody response to vaccination against COVID-19 in people who had been treated for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), patients responded well to two doses of the Moderna mRNA vaccine and saw a pronounced increase in levels ...
TRANSFORM Trial: Lisocabtagene Maraleucel vs Standard of Care for Relapsed or Refractory Large B-Cell Lymphoma
An interim analysis of the TRANSFORM trial comparing the chimeric antigen receptor (CAR) T-cell immunotherapy lisocabtagene maraleucel to standard of care found that the CAR T-cell therapy significantly improved event-free survival for patients with large B-cell lymphoma that persisted or returned...
Activity of Mosunetuzumab in Pretreated Patients With Relapsed or Refractory Follicular Lymphoma
The bispecific antibody mosunetuzumab achieved deep and durable remissions as monotherapy in patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy, according to pivotal results of a phase I/II trial presented at the 2021 American Society of...
Study Reveals Underrepresentation of AYA Hispanic Patients in a Large ALL Clinical Trial
A study of U.S. adolescent and young adult patients with acute lymphoblastic leukemia (ALL) found that Hispanic patients were significantly underrepresented in a large clinical trial compared with the general patient population. The study, presented by Muffly et al at the 2021 American Society of...
Outcomes Among Pediatric and Young Adult Patients With ALL Differ By Race, Ethnicity, and Socioeconomic Status
A study of nearly 25,000 patients with acute lymphoblastic leukemia (ALL) aged up to 30 years old revealed significant gaps in survival rates between White, Hispanic, and Black patients, as well as worse outcomes among those of lower socioeconomic status. Biologic or genetic factors accounted for...
The National Cancer Act of 1971
On December 23, 1971, President Richard M. Nixon signed the National Cancer Act into law. At that time, cancer was the nation’s second leading cause of death; only about one of two people diagnosed with cancer survived at least 5 years—compared with two of three people diagnosed with the disease...
